Skip to content

US · OTLK · BIOTECHNOLOGY

Outlook Therapeutics, Inc. (OTLK) intrinsic value and stock valuation

$0.39as of 2026-11-21 · Mkt cap 123.28M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Outlook Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values OTLK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OTLK’s statements →

Outlook Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Iselin, NJ 08830 outlooktherapeutics.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$1.41M
20142025
Net income
-$-62.42M
20142025
Free cash flow
-$-51.83M
20142025
Total equity
-$-32.19M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$1.41M$0.00$0.00$0.00$0.00
Operating income-$-67.06M-$-71.7M-$-53.13M-$-63.07M-$-51.73M
Net income-$-62.42M-$-75.37M-$-58.98M-$-66.05M-$-53.16M
EPSd-$-2.45M-$-4.06M-$-4.71M-$-6.23M-$-6.97M
Operating cash flow-$-51.83M-$-68.79M-$-42.97M-$-56.67M-$-54.25M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-51.83M-$-68.79M-$-42.97M-$-56.67M-$-54.25M
Total assets$18.6M$28.8M$32.3M$28.5M$22.8M
Total debt$30.2M$29.7M$35.6M$11M$11.9M
Net debt$22.1M$14.8M$12.2M-$-6.44M-$-2.57M
Total equity-$-32.19M-$-73.08M-$-14.44M$8.74M$4.61M
Cash and short-term investments$8.08M$14.9M$23.4M$17.4M$14.5M
Income statement
20252024202320222021
Revenue$1.41M$0.00$0.00$0.00$0.00
Cost of revenue$760K$110K$40K$200K$260K
Gross profit$660K-$-110K-$-40K-$-200K-$-260K
Research and development expenses$27.2T$41.8M$26.5M$42.3M$39M
Selling, general and administrative expenses$39.9M$29.9M$26.7M$20.7M$12.8M
Other expenses-$-27.18T$0.00$0.00-$-200K$0.00
Operating expenses$67.7M$71.7M$53.1M$62.9M$51.7M
Cost and expenses$68.5M$71.7M$53.1M$63.1M$51.7M
Interest income$90K$910K$0.00$0.00$0.00
Interest expense$280K$3.16M$1.56M$1.49M$940K
Depreciation and amortization$120K$110K$40K$200K$260K
Ebitda-$-63.58M-$-72.09M-$-57.38M-$-64.36M-$-51.51M
Operating income-$-67.06M-$-71.7M-$-53.13M-$-63.07M-$-51.73M
Total other income/expenses, net$3.08M-$-3.66M-$-5.85M-$-2.98M-$-1.43M
Income before tax-$-63.98M-$-75.36M-$-58.98M-$-66.05M-$-53.16M
Income tax expense-$-1.55M$0.00$0.00$0.00$0.00
Net income-$-62.42M-$-75.37M-$-58.98M-$-66.05M-$-53.16M
Weighted average shares outstanding$34.8M$18.6M$12.5M$10.6M$7.63M
Weighted average diluted shares outstanding$25.5M$18.6M$12.5M$10.6M$7.63M
Balance sheet
20252024202320222021
Cash and short-term investments$8.08M$14.9M$23.4M$17.4M$14.5M
Net receivables$1.49M$0.00$0.00$0.00$0.00
Inventory$3.34M$0.00$0.00$0.00$0.00
Total current assets$17.4M$27.4M$31M$27.5M$21.5M
Property, plant and equipment, net$230K$270K$30K$70K$280K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$550K$690K$790K$800K$850K
Total non-current assets$1.2M$1.41M$1.32M$1.01M$1.3M
Total assets$18.6M$28.8M$32.3M$28.5M$22.8M
Accounts payable$10.2M$7.97M$6.57M$3.49M$2.2M
Short-term debt$30M$29.5M$35.6M$11M$970K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$45.8M$42.6M$46.7M$19.7M$6.75M
Long-term debt$190K$250K$0.00$0.00$10.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.96M$59.4M$10K$60K$11.5M
Capital lease obligations$250K$300K$0.00$40K$110K
Total liabilities$50.8M$101.9M$46.7M$19.8M$18.2M
Common stock$540K$240K$2.6M$2.27M$1.76M
Retained earnings-$-605.71M-$-543.28M-$-467.92M-$-408.94M-$-342.88M
Accumulated other comprehensive income (loss)$0.00$0.00-$-32.3T$417.7M-$-22.81T
Total equity-$-32.19M-$-73.08M-$-14.44M$8.74M$4.61M
Total investments$550K$690K$790K$800K$850K
Total debt$30.2M$29.7M$35.6M$11M$11.9M
Net debt$22.1M$14.8M$12.2M-$-6.44M-$-2.57M
Cash flow statement
20252024202320222021
Net income-$-62.42M-$-75.37M-$-58.98M-$-66.05M-$-53.16M
Depreciation and amortization$120K$110K$40K$200K$260K
Stock-based compensation$8.9M$5.39M$5.55M$7.71M$4.89M
Change in working capital$4.86M-$-3.02M$4.75M-$-1.68M-$-7.08M
Accounts receivable-$-1.49M$0.00$0.00$0.00$0.00
Inventory-$-3.34M$0.00$0.00$0.00$0.00
Accounts payable$1.67M$1.39M$3.08M$1.3M-$-200K
Net cash provided by operating activities-$-51.83M-$-68.79M-$-42.97M-$-56.67M-$-54.25M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$48M$60.3M$30M$62.3M$46.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$45M$60.3M$49M$59.6M$56.2M
Net change in cash-$-6.84M-$-8.46M$6M$2.92M$1.94M
Cash at end of period$8.08M$14.9M$23.4M$17.4M$14.5M
Operating cash flow-$-51.83M-$-68.79M-$-42.97M-$-56.67M-$-54.25M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-51.83M-$-68.79M-$-42.97M-$-56.67M-$-54.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Outlook Therapeutics, Inc.

        Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

        CEO
        Robert Charles Jahr
        Employees
        17
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Outlook Therapeutics, Inc. (OTLK)?

        InvestorsCraft does not currently publish an intrinsic value for OTLK. How the IC value is calculated.

        Is OTLK undervalued?

        InvestorsCraft does not publish an undervaluation signal for OTLK at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.